/R E P E A T -- Media Advisory - CRTC to hold a Public Hearing on making it easier for consumers to shop for Internet services/ Français
GATINEAU, QC, June 9, 2025 /CNW/ - The Canadian Radio-television and Telecommunications Commission (CRTC) will hold a public hearing, beginning on June 10, 2025, at the Conference Centre, Phase IV, 140 Promenade du Portage, Gatineau, Quebec.
This hearing will examine submissions and public views on how to make shopping for home Internet services easier for Canadians. It is part of the CRTC's broader effort to help Canadians make informed choices.
If you are interested in following the hearing and obtaining documents during the hearing, follow us @CRTCHearings and https://video.isilive.ca/crtc/2025/english.html.
Reference Documents:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
GTA Residents Sound Alarm: Nearly 80% Call Auto Theft a Crisis
2024 auto theft claims data shows slight improvement over 2023, but most GTA residents fear their vehicle will be stolen TORONTO , June 12, 2025 /CNW/ - New data from Insurance Bureau of Canada (IBC) confirms Ontario remains in the midst of an auto theft crisis, with the number of insurance claims up 165% since 2017 and the costs to service those claims up a staggering 538%. Even more troubling is how residents of the Greater Toronto Area (GTA) – where the vast majority of vehicles are stolen – view the auto theft crisis. According to a new Pollara Strategic Insights poll commissioned by IBC, 63% of GTA residents live in fear of their vehicle being stolen and more than half (56%) reporting that the crisis is affecting their community. Continue Reading Auto Theft Claims in Ontario (CNW Group/Insurance Bureau of Canada) "We still have a long way to go to effectively curb auto theft in the province," said Amanda Dean , Vice-President, Ontario and Atlantic, IBC. "The Ontario and federal government's efforts to tackle auto theft are both commendable and were reflected in the decline in claims costs in 2024. But the crisis persists and requires continued leadership and focus." Over the past eight years, auto theft has disrupted thousands of lives and families across Ontario and placed an unprecedented strain on law enforcement, court resources and insurance costs. According to the recent auto theft survey commissioned by IBC, the emotional toll this crisis is having on residents is alarming: 76% believe Ontario is facing an auto theft crisis. is facing an auto theft crisis. 63% of GTA residents are concerned that a vehicle they own, co-own or lease might be stolen in the future. Younger Ontarians express more concern; 75% of those aged 18–34 and 67% of those aged 35–54 are worried about their vehicle being stolen, compared to 52% of those aged 55+. 56% say the crisis is affecting their own community. Auto theft in Ontario Insurance Claims and Costs for Auto Theft, 2017 to 2024 Claims Count Total Cost 2017 7,693 $113,627,636 2018 9,470 $165,474,435 2019 10,426 $211,783,676 2020 10,547 $242,929,120 2021 13,632 $406,390,578 2022 20,497 $760,035,984 2023 25,805 $1,036,937,925 2024 20,418 $724,598,945 IBC analysis based on industry data from GISA systems. " Ontario's insurers have taken steps to address the crisis and we look forward to supporting the federal government's recently announced Strong Borders Act as it follows through with its recent commitments to add 1,000 new Canada Border Services Agency officers to manage additional border scanners, drones and new canine teams for Canada's land borders, ports and railyards," added Dean. "Last week's announcement will help to close a gap in the transportation network and prevent stolen vehicles from leaving Canada . We need a whole-of-society approach coordinated through continued federal government leadership and a commitment from all stakeholders to put an end to auto theft." About the Pollara survey Pollara Strategic Insights conducted the online survey from April 23 to April 29, 2025 , among N=1,126 adult (18+) GTA residents. The data set has been weighted by age, gender and region to ensure it accurately represents the demographic and geographic distribution of this population. As a guideline, a probability sample of N=1,126 carries a margin of error of ±2.9% 19 times out of 20. Sub-samples carry higher margins of error. About Insurance Bureau of Canada Established in 1964, Insurance Bureau of Canada (IBC) is the national industry association representing Canada's private home, auto and business insurers. Its member companies make up the vast majority of Canada's highly competitive property and casualty (P&C) insurance market. As the leading advocate for Canada's private P&C insurers, IBC collaborates with governments, regulators and stakeholders to support a competitive environment for the P&C insurance industry to continue to help protect Canadians from the risks of today and tomorrow. IBC believes that Canadians value and deserve a responsive and resilient private P&C insurance industry that provides insurance solutions to both individuals and businesses. For media releases, IN Focus articles, or to book an interview with an IBC representative, visit . Follow us on LinkedIn , X and Instagram, and like us on Facebook . If you have a question about home, auto or business insurance, contact IBC's Consumer Information Centre at 1-844-2ask-IBC. We're here to help. SOURCE Insurance Bureau of Canada Media Contact: Brett Weltman, Manager, Media Relations, IBC, [email protected]
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
‘An underlying epidemic': Elder financial abuse on the rise as population ages
As Canada's population ages, it's been estimated that over $1.1 trillion in assets is on the move from baby boomers to gen X and millennials as part of 'the great wealth transfer.' Despite many elderly Canadians having carefully arranged inheritance plans in place, seniors' advocates and financial crime experts are warning they have become increasingly vulnerable to attempts to exploit their money. Ahead of World Elder Abuse Awareness Day on Sunday, they said it's important for Canadians, including both seniors and their loved ones, to educate themselves about these growing risks. Financial abuse is the most common form of elder abuse in Canada, said Holly Cunliffe, a partner at Aird & Berlis specializing in elder law. 'We have a lot of older adults in our population and so we are definitely seeing an increase in instances of financial abuse affecting our older populations,' said Cunliffe, a member of the Society of Trust and Estate Practitioners, a professional body comprised of lawyers, accountants and financial advisers. She and other experts said seniors generally experience financial abuse in two ways. While financial scams are on the rise, including digital fraud attempts specifically targeting older victims, there is also a growing risk of abuse at the hands of a person the senior already knows. Cunliffe calls the latter form 'an underlying epidemic' that too often flies below the radar. It typically involves someone with power of attorney — a legal document that gives them authority to act on a vulnerable person's behalf — exploiting the designation to their own benefit. 'Unfortunately, that means friends and family can actually be the perpetrators,' she said. 'If those documents are not prepared early enough in time before there's any potential for diminished capacity or influence, then it is possible that family members … can seek to have those documents prepared for their own personal gain.' Even if a trusted loved one has every intent to act appropriately, a lack of understanding of the scope of their role and its limits can inadvertently lead to financial abuse, said Cunliffe. Bénédicte Schoepflin, executive director of the Canadian Network for the Prevention of Elder Abuse, said elder financial abuse usually relies on a trusting relationship. Around 81 per cent of reported cases are carried out by a spouse, family member, friend or acquaintance. Financial mistreatment 'doesn't always happen in a confrontational or violent way,' said Schoepflin, adding: 'Sometimes it is really more about the trickery of it all.' 'It can be really difficult to recognize that what is happening is not OK,' she said. 'It can start in a manner that feels like it's not a big amount or not a big deal, (like), 'Well, I voluntarily shared my PIN number with my grandson because he was helping me to go get groceries' and then … there's a gradual slide into bigger, more serious forms of abuse.' Schoepflin said vulnerability also has an intersectional element. The risk of being victimized is higher for woman, seniors who have experienced mistreatment earlier in life, those who identify as a person of colour, along with those living with someone financially dependent on them. 'People choose to stay silent because they do not want to create issues within their own closed circles,' she said. 'The person who is experiencing abuse might not want to be in that situation, but still might also not want to create trouble for the person who is harming them or taking advantage of them, or might not want to upset a family balance.' Cunliffe said the risk of being exploited is even greater for Canadians with cognitive decline, including those living with diseases such as dementia or Alzheimer's. 'The older the person is, the greater the risk of cognitive decline, and with that decline comes the risk of an increased vulnerability to financial abuse,' she said. The other category of financial abuse — incidents in which the perpetrator, such as a scammer, is not known to the victim — is also a growing threat, said Larry Zelvin, head of BMO's financial crimes unit. He said technologies such as AI are making scams more sophisticated and harder for older adults to detect. Nowadays, AI-powered tools can be used to generate realistic phishing emails, while deepfake technology can even enable scammers to impersonate family members or trusted advisers. 'Some of them might be less digitally competent … which also makes them more vulnerable,' said Zelvin. He added seniors are targeted especially because they have often already accumulated wealth. 'As you get older, unfortunately, you become more isolated,' he said. 'Older folks, especially those who are missing those social interactions, are maybe more trusting in nature than they would have been otherwise.' He said his advice is that if an out-of-the-blue offer 'sounds too good to be true, it probably is.' Monday Mornings The latest local business news and a lookahead to the coming week. Zelvin also encouraged seniors to come forward if they suspect they've been a victim of financial exploitation, noting cases are vastly under-reported to authorities such as the Canadian Anti-Fraud Centre, RCMP or local law enforcement. While it might seem embarrassing to admit, he said those targeted should feel no different than if they were reporting any other crime, like if their car had been stolen. 'You've been a victim. You are not culpable,' he said. 'You're not just reporting it. You may be preventing other people from having to go through what you went through.' This report by The Canadian Press was first published June 12, 2025.
Cision Canada
an hour ago
- Cision Canada
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in AI, diagnostics, and even exercise-based interventions, this year's gathering spotlighted a broad array of promising approaches. However, looming over the scientific excitement are concerns about proposed U.S. budget cuts, including a potential 40% reduction in funding for the National Cancer Institute (NCI). As public investment comes under pressure, many are turning to the private sector to carry the load — with recent moves by companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Anixa Biosciences, Inc. (NASDAQ: ANIX), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and ImmunityBio, Inc. (NASDAQ: IBRX). The rising global burden of cancer is driving urgent demand for next-generation therapies. By 2030, annual case counts are expected to climb 20%, with projections pointing to a 75% surge by 2050, according to Statista. Market researchers anticipate oncology spending will scale to match: ResearchAndMarkets forecasts the sector hitting US$866.1 billion by 2034, growing at a 10.8% CAGR, while Vision Research Reports places the market for cancer treatments even higher — surpassing US$903.81 billion at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls — and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. In other recent industry developments and happenings in the market include: Anixa Biosciences, Inc. (NASDAQ: ANIX) is advancing two novel programs at the frontlines of cancer immunotherapy. The company will present new data from its first-in-human ovarian cancer CAR-T clinical trial later this month at the ESMO Gynaecological Cancers Congress, showcasing a unique chimeric endocrine receptor T-cell (CER-T) platform targeting the follicle stimulating hormone receptor (FSHR). Separately, Anixa is also working with Cleveland Clinic to develop a preventative breast cancer vaccine designed to train the immune system to recognize "retired" proteins reactivated in early malignancies. "While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment." Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has published the final five-year analysis from its Phase 2 C-144-01 trial evaluating Amtagvi® (lifileucel), the first FDA -approved T cell therapy for solid tumors in patients with advanced melanoma. "Amtagvi has demonstrated long-term benefit and meaningful overall survival in a difficult-to-treat melanoma patient population resistant to immune checkpoint inhibitor therapy," said Theresa Medina, M.D., medical oncologist at the University of Colorado Cancer Center on the Anschutz Medical Campus. "Five years following one-time Amtagvi treatment, responses persisted or deepened during an extended treatment-free interval for some patients. Amtagvi offers a new standard of care for the advanced melanoma community and sets a new bar for one-time cell therapies with curative intent in solid tumors." The results, featured in the Journal of Clinical Oncology and presented at ASCO 2025, highlight durable responses in heavily pretreated patients—with nearly one-third of responders maintaining benefit five years after a single treatment. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently reported compelling Phase 3 results for Libtayo® (cemiplimab) as an adjuvant therapy in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial showed a 68% reduction in disease recurrence or death and strong secondary endpoint performance, including 80% and 65% reductions in locoregional and distant recurrence, respectively. "The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk CSCC, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence," said Danny Rischin, M.D., Head of Head and Neck Cancer and Cutaneous SCC at Peter MacCallum Cancer Centre. "While surgery and radiotherapy remain the cornerstones of treatment, there is a critical unmet need for systemic therapies to help prevent relapse and metastasis." Regulatory filings have already been submitted in the U.S. and EU, and experts say these findings could reshape treatment standards. ImmunityBio, Inc. (NASDAQ: IBRX) is advancing what may be the first true therapy for lymphopenia—a condition long associated with poor outcomes in cancer but never directly treated until now. "Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. " Backed by FDA Expanded Access authorization, the company's Cancer BioShield™ platform centers on ANKTIVA®, an IL-15 superagonist approved in bladder cancer and now being deployed to help restore immune function in patients with solid tumors who've exhausted first-line therapies. "This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA," said Soon-Shiong. "The survival benefit we observed at ASCO 2025 in 3 rd to 6 th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels—rather than depleting them—can change the course of disease." At ASCO 2025, ImmunityBio presented landmark data showing that reversing lymphopenia with ANKTIVA and CAR-NK cells significantly extended survival in late-stage pancreatic cancer patients, especially when intervention occurred at a lower tumor burden. The results represent a potential paradigm shift: treating immune collapse itself—not just the tumor—may drive better long-term outcomes. Based on this mechanism, the platform could open doors to broader applications in oncology, infectious disease, and immune senescence. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
